Biotech companies had to lower their pricing before floating on public markets.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
IPO floodgates unlikely to open after Ark floatation
Companies jostle for access to public markets
Related external links
Rights and permissions
About this article
Cite this article
Mitchell, P. IPO plans sour on both sides of the pond. Nat Biotechnol 22, 929–930 (2004). https://doi.org/10.1038/nbt0804-929
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0804-929
This article is cited by
-
Acquisition signals shift from US market
Nature Biotechnology (2005)
-
Early-stage biotechs raising more cash in Europe
Bioentrepreneur (2004)